Abstract
The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. In many situations, the patient and physician have the responsibility to jointly explore and select the most appropriate option from among the available alternatives. With rare exceptions, the evaluation, treatment, and follow-up recommendations in these guidelines are based on the results of past and present clinical trials. However, there is not a single clinical situation in which the treatment of breast cancer has been optimized with respect to either maximizing cure or minimizing toxicity and disfigurement. Therefore, patient/physician participation in prospective clinical trials allows patients to not only receive state-of-the-art cancer treatment, but also to contribute to improving the treatment of future patients.
Original language | English (US) |
---|---|
Pages (from-to) | 238-289 |
Number of pages | 52 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 3 |
Issue number | 3 |
DOIs | |
State | Published - May 2005 |
Keywords
- Adjuvant therapy
- Breast cancer
- Breast-conserving therapy
- Chemotherapy
- Ductal carcinoma in situ
- Endocrine therapy
- Lobular carcinoma in situ
- Mastectomy
- NCCN Clinical Practice Guidelines
- Radiation therapy
ASJC Scopus subject areas
- Oncology